

Review Article

# Navigating Neurogenesis: Small Molecules as Key Players in Astrocyte Differentiation

Sanjeev Gautam<sup>1\*</sup>, Akash Sindhyan<sup>1</sup> and Anal Kant Jha<sup>2</sup>

<sup>1</sup>Department of Biotechnology, Institute of Integrated and Honors Studies, Kurukshetra University, Kurukshetra, Haryana India

<sup>2</sup>Aryabhata Centre for Nanoscience and Nanotechnology Aryabhata Knowledge University, CNLU Campus, Patna, India

Received 20 May 2022, Accepted 30 June 2022, Available online 02 July 2022, Vol.11 (2022)

## Abstract

*Astrocytes play a critical role in maintaining the central nervous system (CNS) homeostasis, supporting neuronal function, and responding to injury. Recent advances in stem cell biology have highlighted the potential of small molecules to direct the differentiation of astrocytes from pluripotent stem cells. These small molecules offer a powerful tool for both basic research and therapeutic applications, allowing precise control over astrocyte development and function. This review explores the mechanisms by which small molecules influence astrocyte differentiation, focusing on key signaling pathways, transcription factors, and epigenetic modifications. Additionally, we discuss the therapeutic implications of small molecule-induced astrocyte differentiation in neurodegenerative diseases, CNS injuries, and other neurological conditions. The review also outlines future directions for research in this rapidly evolving field, emphasizing the need for further exploration of small molecules' role in astrocyte biology and their potential for clinical translation.*

**Keywords:** Astrocyte differentiation, small molecules, neurogenesis, CNS homeostasis, pluripotent stem cells, neurodegenerative diseases, epigenetics, signaling pathways.

## Introduction

Astrocytes, the star-shaped glial cells of the CNS, are indispensable for maintaining neuronal health, regulating blood-brain barrier integrity, and modulating synaptic activity. They have emerged as critical players in the CNS, not just as supporting cells but also as active participants in neurogenesis, synaptic plasticity, and response to injury (Sofroniew & Vinters, 2010). The ability to generate astrocytes in vitro through the differentiation of pluripotent stem cells has opened new avenues for research and therapeutic intervention, particularly in neurodegenerative diseases and CNS injuries (Krencik & Ullian, 2013).

Small molecules have been identified as potent modulators of stem cell fate, offering precise control over the differentiation process. Unlike genetic manipulation, small molecules can be applied transiently and reversibly, making them ideal tools for directing cell fate in a controlled manner (Xu *et al.*, 2008). The use of small molecules in astrocyte differentiation has gained significant attention due to their ability to activate or inhibit specific signaling pathways, modulate transcription factor activity, and influence epigenetic landscapes (Chambers *et al.*, 2009).

Key signaling pathways such as the JAK/STAT, BMP, and Wnt pathways have been shown to play crucial roles in astrocyte differentiation, with small molecules serving as either agonists or antagonists of these pathways (Bonaguidi *et al.*, 2005; Miller & Gauthier, 2007).

Moreover, astrocytes generated through small molecule-guided differentiation have been utilized in disease modeling, drug screening, and regenerative medicine. For instance, in models of neurodegenerative diseases such as Alzheimer's and Parkinson's, astrocytes differentiated in vitro have provided insights into disease mechanisms and have served as platforms for testing therapeutic compounds (Zhang *et al.*, 2016). The potential of small molecules in this context is immense, as they not only enhance the efficiency of differentiation but also allow for the generation of astrocytes with specific phenotypes relevant to various CNS disorders.

This review delves into the current understanding of the role of small molecules in astrocyte differentiation. We discuss the molecular mechanisms underlying this process, the therapeutic applications of astrocytes generated through small molecule modulation, and the future directions in this exciting field of research.

## What Are Small Molecules?

Small molecules are low molecular weight organic compounds that can easily diffuse across cell

\*Corresponding author's email: [sgautam@kuk.ac.in](mailto:sgautam@kuk.ac.in)

membranes. They are often used in pharmacology and cell biology to modulate biological processes, including signal transduction pathways, gene expression, and enzyme activity (Harrison, 2016). Unlike larger biologics, small molecules can interact with intracellular targets, making them valuable tools for manipulating cellular functions, including the differentiation of stem cells into specific cell types like astrocytes (Schreiber, 2000).

These molecules can be designed to activate or inhibit specific signaling pathways, providing a high degree of control over cellular outcomes. For example, small molecules can modulate the activity of transcription factors, enzymes, and receptors involved in stem cell differentiation (Xu *et al.*, 2008). Their ability to cross the blood-brain barrier also makes them particularly useful in CNS research and therapy (Pardridge, 2012).

### Mechanisms of Small Molecule-Induced Astrocyte Differentiation

The differentiation of astrocytes from stem cells is orchestrated by a complex interplay of signaling pathways, transcription factors, and epigenetic modifications. Small molecules have been shown to modulate these processes, thereby directing stem cells towards an astrocytic lineage (Chambers *et al.*, 2009).

1. **JAK/STAT Pathway:** The JAK/STAT pathway is a major signaling cascade involved in astrocyte differentiation. Small molecules that activate this pathway, such as leukemia inhibitory factor (LIF) and ciliary neurotrophic factor (CNTF), have been shown to promote the differentiation of astrocytes from neural progenitor cells (Bonaguidi *et al.*, 2005).
2. **BMP Signaling:** Bone morphogenetic proteins (BMPs) are known to induce astrocyte differentiation by inhibiting neuronal and oligodendrocyte differentiation. Small molecules that enhance BMP signaling, such as dorsomorphin, have been used to promote astrocyte formation in vitro (Miller & Gauthier, 2007).
3. **Wnt Signaling:** The Wnt/ $\beta$ -catenin pathway plays a dual role in CNS development, regulating both the proliferation of neural progenitors and their differentiation into astrocytes. Small molecules like CHIR99021, a GSK-3 $\beta$  inhibitor, have been shown to modulate Wnt signaling and promote astrocyte differentiation (Li *et al.*, 2018).
4. **Epigenetic Modulation:** Epigenetic modifications such as DNA methylation and histone acetylation are crucial for the regulation of gene expression during astrocyte differentiation. Small molecules like valproic acid (a histone deacetylase inhibitor) and 5-azacytidine (a DNA methyltransferase inhibitor) have been utilized to influence these epigenetic marks, thereby promoting astrocyte differentiation (Hirabayashi & Gotoh, 2010).

### Therapeutic Implications in Neurodegenerative Diseases

The use of small molecules to direct astrocyte differentiation holds significant promise for the treatment of various neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), and multiple sclerosis (MS). These conditions are marked by the progressive loss of neurons and glial cells, leading to cognitive and motor impairments. Astrocytes, which play supportive roles in the CNS, are increasingly recognized as key players in the pathophysiology of these diseases. Harnessing the power of small molecules to generate astrocytes with neuroprotective and neuroregenerative properties could revolutionize therapeutic approaches.

#### Alzheimer's Disease (AD)

In AD, astrocytes are involved in both neuroprotection and neuroinflammation. They play a critical role in clearing amyloid-beta ( $A\beta$ ) plaques, a hallmark of AD. As the disease progresses, astrocytes may become dysfunctional, contributing to synaptic failure and neuronal death (Medeiros & LaFerla, 2013). Small molecules that promote the differentiation of astrocytes with enhanced  $A\beta$  clearance capabilities could potentially slow AD progression. For instance, retinoic acid promotes the differentiation of astrocytes that are more efficient at degrading  $A\beta$  peptides, suggesting a therapeutic avenue (Ding *et al.*, 2008). Additionally, small molecules that modulate astrocyte inflammatory responses, such as minocycline, have shown promise in reducing neuroinflammation and protecting neurons in AD models (Plane *et al.*, 2010).

#### Parkinson's Disease (PD)

PD is characterized by the degeneration of dopaminergic neurons in the substantia nigra, leading to motor deficits. Astrocytes in this region support neuronal survival and function by providing trophic support, regulating extracellular glutamate, and maintaining the blood-brain barrier. Small molecules that direct astrocyte differentiation to support dopaminergic neurons offer a promising therapeutic strategy for PD (Kim *et al.*, 2020). For example, molecules enhancing neurotrophic factors like glial cell line-derived neurotrophic factor (GDNF) secretion from astrocytes are explored for their potential to protect and regenerate dopaminergic neurons (Akerblom *et al.*, 2012). Rasagiline, a drug with neuroprotective properties, has been investigated for its ability to influence astrocyte function and support neuronal survival in PD models (Youdim, 2010).

#### Amyotrophic Lateral Sclerosis (ALS)

In ALS, astrocytes are implicated in selective motor neuron degeneration. Dysfunctional astrocytes may

release toxic factors, fail to clear glutamate effectively, or become pro-inflammatory, contributing to motor neuron death (Di Giorgio *et al.*, 2007). Small molecules promoting the differentiation of astrocytes with neuroprotective properties show promise in preclinical ALS models. For example, riluzole, the only FDA-approved drug for ALS, modulates glutamate transmission, potentially affecting astrocyte function and providing neuroprotection (Bellingham, 2011). Additionally, molecules that promote astrocyte-mediated clearance of toxic proteins, such as TDP-43 and SOD1, implicated in ALS pathogenesis, are being explored as potential therapeutic agents (Haidet-Phillips *et al.*, 2011). Furthermore, small molecules that modulate astrocyte inflammatory responses, such as dexamethasone, have been studied for their ability to reduce neuroinflammation and slow disease progression in ALS models (Zhao *et al.*, 2006).

### Huntington's Disease (HD)

HD is a neurodegenerative disorder caused by a mutation in the huntingtin gene, leading to the progressive loss of neurons in the striatum and cortex. Astrocytes in HD are thought to be dysfunctional, contributing to neuronal excitotoxicity and death (Faideau *et al.*, 2010). Small molecules that restore normal astrocyte function or promote the differentiation of astrocytes with neuroprotective capabilities may offer new therapeutic avenues for HD. For example, kynurenic acid, an astrocyte-derived metabolite that antagonizes excitotoxicity, has been explored for its neuroprotective potential in HD (Zwilling *et al.*, 2011). Additionally, small molecules enhancing brain-derived neurotrophic factor (BDNF) production by astrocytes have been investigated as a strategy to protect striatal neurons and slow HD progression (Graham *et al.*, 2010).

### Multiple Sclerosis (MS)

MS is a demyelinating disease where astrocytes play a complex role. While they contribute to the inflammatory response and scarring (gliosis), they also have the potential to promote remyelination and repair (Lassmann, 2014). Small molecules that promote a reparative astrocyte phenotype have significant therapeutic potential in MS. For example, bztropine has been shown to promote the differentiation of oligodendrocyte precursor cells (OPCs) into myelinating cells, partly through astrocyte-mediated mechanisms, offering a potential therapeutic approach for MS (Deshmukh *et al.*, 2013). Moreover, molecules reducing astrocyte-mediated inflammation, such as dimethyl fumarate, have been approved for MS treatment, highlighting the therapeutic relevance of modulating astrocyte function in this disease (Linker & Haghikia, 2016).

The field of small molecule-induced astrocyte differentiation is rapidly evolving, with several exciting avenues for future research. One key area is the identification and characterization of novel small

molecules that can more precisely control the differentiation process. High-throughput screening technologies and chemical libraries could facilitate the discovery of new compounds with unique properties (Wang *et al.*, 2017).

Additionally, the development of three-dimensional (3D) culture systems and organoids offers new opportunities for studying astrocyte differentiation in a more physiologically relevant context. These models could provide deeper insights into the role of small molecules in astrocyte development and their potential therapeutic applications (Qian *et al.*, 2020).

Another promising direction is the use of small molecules in combination with gene editing technologies, such as CRISPR/Cas9, to achieve more targeted and efficient differentiation of astrocytes. This approach could enable the generation of astrocytes with specific genetic modifications, providing valuable tools for studying disease mechanisms and developing personalized therapies (Schwartz & Wang, 2020).

Finally, the translation of small molecule-induced astrocyte differentiation into clinical applications remains a major challenge. Future research should focus on optimizing protocols for generating astrocytes suitable for transplantation and developing strategies to ensure their survival and integration into the host CNS (Li *et al.*, 2018).

### Challenges in Small Molecule-Induced Astrocyte Differentiation

Despite the promising therapeutic potential, there are several challenges associated with using small molecules to induce astrocyte differentiation. One major hurdle is the complexity of astrocyte biology itself; these cells are highly heterogeneous, with diverse subtypes that perform distinct functions across different regions of the CNS. Identifying small molecules that can selectively promote the differentiation of specific astrocyte subtypes without unintended effects on other cell types is a significant challenge. Additionally, the long-term effects of manipulating astrocyte differentiation are not fully understood, raising concerns about potential off-target effects, including tumorigenesis or the disruption of normal CNS function. Another challenge lies in the delivery of these small molecules to the CNS, as the blood-brain barrier (BBB) poses a significant obstacle to drug penetration. Developing effective delivery systems that can cross the BBB and target specific regions of the brain remains a critical area of research. Furthermore, translating findings from animal models to human clinical applications is complicated by species differences in astrocyte biology, requiring careful consideration in the design of therapeutic strategies. Addressing these challenges will be crucial for advancing small molecule-based therapies for neurodegenerative diseases.

### Future Directions

The future of small molecule-induced astrocyte differentiation lies in overcoming current challenges

and expanding our understanding of astrocyte biology. High-throughput screening for new small molecules that selectively promote specific astrocyte subtypes will be crucial for advancing therapeutic applications. Additionally, integrating small molecules with other therapeutic modalities, such as gene editing and stem cell transplantation, holds the potential for more effective and comprehensive treatments for neurodegenerative diseases.

Advances in organoid technology and 3D bioprinting could provide more physiologically relevant models for testing small molecules in the context of human disease (Li et al., 2018). These models could help bridge the gap between preclinical studies and human applications, providing more accurate predictions

## Conclusions

Small molecules have emerged as powerful tools for directing astrocyte differentiation, offering precise control over the development of these critical CNS cells. The ability to generate astrocytes in vitro through the modulation of specific signaling pathways, transcription factors, and epigenetic marks has significant implications for basic research, disease modeling, and therapeutic development. While there are still challenges to be addressed, including the optimization of differentiation protocols and the translation of these findings into clinical applications, the potential of small molecules in astrocyte differentiation is undeniable. Future research in this area is likely to yield new insights into astrocyte biology and open up novel therapeutic avenues for neurodegenerative diseases and other CNS disorders.

## References

- Bonaguidi, M. A., McGuire, T., Hu, M., Kan, L., Samanta, J., & Kessler, J. A. (2005). LIF and BMP signaling cooperatively regulate neural stem cell identity. *Developmental Biology*, 288(1), 48-62.
- Chambers, S. M., Fasano, C. A., Papapetrou, E. P., Tomishima, M., Sadelain, M., & Studer, L. (2009). Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. *Nature Biotechnology*, 27(3), 275-280.
- Di Giorgio, F. P., Carrasco, M. A., Siao, M. C., Maniatis, T., & Eggan, K. (2007). Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model. *Nature Neuroscience*, 10(5), 608-614.
- Hirabayashi, Y., & Gotoh, Y. (2010). Epigenetic control of neural precursor cell fate during development. *Nature Reviews Neuroscience*, 11(6), 377-388.
- Kim, J. Y., Kim, H. J., Kim, H. J., & Kim, J. H. (2020). Dopaminergic neuron protection by astrocyte-conditioned medium in a Parkinson's disease model. *Scientific Reports*, 10(1), 11108.
- Krencik, R., & Ullian, E. M. (2013). A cellular star rising: Astrocytes as therapeutic targets in neurological disorders. *Annual Review of Pharmacology and Toxicology*, 53, 409-429.
- Li, Y., Zhang, X., Gao, J., Zhang, X., Guo, S., & Hu, X. (2018). 3D bioprinting of neural tissue for neurodegenerative disease modeling. *Advanced Healthcare Materials*, 7(7), 1701343.
- Medeiros, R., & LaFerla, F. M. (2013). Astrocytes: Conductors of the Alzheimer disease neuroinflammatory symphony. *Experimental Neurology*, 239, 1-16.
- Miller, F. D., & Gauthier, A. S. (2007). Timing is everything: Making neurons versus glia in the developing cortex. *Neuron*, 54(3), 357-369.
- Qian, X., Song, H., & Ming, G. L. (2020). Brain organoids: Advances, applications, and challenges. *Development*, 147(10), dev166074.
- Schwartz, R., & Wang, J. C. (2020). Gene editing to generate astrocyte models of neurological disorders. *Journal of Neuroscience Research*, 98(2), 217-225.
- Sofroniew, M. V., & Vinters, H. V. (2010). Astrocytes: Biology and pathology. *Acta Neuropathologica*, 119(1), 7-35.
- Takahashi, K., & Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell*, 126(4), 663-676.
- Wang, P., Zhang, Y., Gong, Y., Yang, Z., & Lu, W. (2017). New chemical entity identification for small molecule drug discovery using structure-based virtual screening. *Frontiers in Chemistry*, 5, 45.
- Xu, Y., Shi, Y., & Ding, S. (2008). A chemical approach to stem cell biology and regenerative medicine. *Nature*, 453(7193), 338-344.
- Zhang, Y., Sloan, S. A., Clarke, L. E., Caneda, C., Plaza, C. A., Blumenthal, P. D., & Barres, B. A. (2016). Purification and characterization of progenitor and mature human astrocytes reveals transcriptional and functional differences with mouse. *Neuron*, 89(1), 37-53.
- Barres, B. A. (2008). "The mystery and magic of glia: A perspective on their roles in health and disease." *Neuron*, 60(3), 430-440.
- Bergles, D. E., & Tymiński, M. (2018). "Astrocytes as active participants in synaptic function." *Current Opinion in Neurobiology*, 52, 1-7.
- Gleeson, J. G., & Walsh, C. A. (2000). "Neurogenesis and brain malformations: Genetic insights into the pathogenesis of neurological disorders." *Current Opinion in Genetics & Development*, 10(3), 308-316.
- Goldstein, A. M., & Zhang, H. (2020). "Regulation of astrocyte differentiation and function by small molecules." *Molecular Neurobiology*, 57(10), 4172-4186.
- Hald, J. D., & Lotharius, J. (2005). "Ongoing neuroinflammation and neurodegeneration in Parkinson's disease." *Current Opinion in Neurology*, 18(6), 635-641.
- Hennigan, A., & Lynch, M. A. (2010). "The role of astrocytes in neurodegenerative diseases." *Journal of Alzheimer's Disease*, 22(4), 1-13.
- Kang, S. H., & Kim, M. H. (2016). "Small molecule modulation of astrocyte differentiation: A review of recent advances and future directions." *Pharmacology & Therapeutics*, 165, 129-137.
- Kong, H., & Xu, J. (2017). "Small molecules in neurogenesis and their potential applications in neurodegenerative diseases." *Frontiers in Neuroscience*, 11, 581.
- Lange, S., & van den Berg, R. (2018). "Astrocyte-targeted therapies in neurodegenerative diseases." *Neurotherapeutics*, 15(1), 95-105.
- Liu, Y., & Wu, X. (2019). "The role of astrocytes in neuroinflammation and neurodegenerative diseases." *Journal of Neuroinflammation*, 16(1), 241.
- Miller, R. H., & Gauthier, S. (2007). "Astrocyte development and function: Implications for neurogenesis and neurodegenerative disease." *Neuroscience*, 145(1), 159-171.
- Perea, G., & Araque, A. (2007). "Astrocytes modulate synaptic transmission and plasticity." *Physiology*, 22(1), 1-6.

- Pekny, M., & Pekna, M. (2016). "Astrocyte activation and reactive gliosis in neurological diseases: How do they impact disease progression?" *Neuroscience Letters*, 613, 123-128.
- Popko, B., & McTigue, D. (2007). "Astrocyte dysfunction and neuroinflammation: Insights from animal models." *Journal of Neuroimmunology*, 185(1-2), 84-93.
- Rivetti, C., & Cova, L. (2019). "Small molecules targeting astrocyte differentiation and their potential therapeutic applications." *Molecular Therapy*, 27(4), 623-634.
- Schneider, A., & Schuster, T. (2018). "Role of small molecules in astrocyte biology and their implications in neurodegenerative diseases." *Frontiers in Cellular Neuroscience*, 12, 90.
- Sofroniew, M. V., & Vinters, H. V. (2010). "Astrocytes: Biology and pathology." *Acta Neuropathologica*, 119(1), 7-35.
- Stolp, H. B., & Dziegielewska, K. M. (2009). "Developmental aspects of the blood-brain barrier." *Current Topics in Developmental Biology*, 88, 145-160.
- Tzeng, Y. H., & Lu, Y. C. (2021). "The role of small molecules in regulating astrocyte function and differentiation in neurodegenerative diseases." *Neurobiology of Disease*, 150, 105272.
- Wang, J., & Zhang, Y. (2020). "Small molecules in neural stem cell differentiation: Mechanisms and therapeutic potential." *Stem Cells Translational Medicine*, 9(4), 498-507.